While multiple sclerosis (MS) has traditionally been thought of as being a T-cell mediated disease, an increasing body of evidence suggests that B cells and autoantibodies are involved in the pathology of MS, providing support for the use of treatments directed against B cells.
In secondary-progressive multiple sclerosis (SPMS), patients show worsening gait disorder and ambulatory dysfunction that require the use of a cane, a walker, or a wheelchair. Treatment options for SPMS are limited, but several new therapies show promise.
Adherence is defined as conforming to the recommendations made by the provider with respect to timing, dosage, and frequency of medication taking, and following these recommendations is important for patients with multiple sclerosis (MS) to fully benefit from disease-modifying therapies (DMTs).
Fumaric acid esters (FAEs) are a known component of a centuries-old herbal medicine, have been used for over 50 years as a topical treatment for psoriasis, and most recently, have demonstrated efficacy in treating relapsing- remitting multiple sclerosis.
In a phase II trial, combination treatment with Gilead's simeprevir (Olysio) and Janssen's simeprevir (Sovaldi) yielded functional cure rates exceeding 90% in patients with hepatitis C virus (HCV) who received 12 weeks of therapy-even among difficult-to-treat patients.
The Fair Pricing Coalition (FPC) works closely with the pharmaceutical industry to ensure patient access to copay and patient assistant programs (PAPs) for people with HCV. Most pharmaceutical companies have collaborated with the FPC to coordinate programs that are typically based on income adjusted for family and/or household size.
The clinical management of patients with hepatitis C virus (HCV) infection represents an ideal opportunity for the benefits of precision medicine and the individualization of patient care. This is particularly true given the importance of genetic and nongenetic factors that have recently been identified as critical to HCV infection management.
An estimated 3.3% of people in the United States born between 1945 and 1965 have chronic hepatitis C infection. The increased risk of infection in this population has recently led the Centers for Disease Control and Prevention (CDC) to recommend one-time hepatitis C virus (HCV) testing for all persons in this age cohort.
On March 21, 2014, the US Food and Drug Administration announced the approval of Celgene Corporation's Otezla (apremilast), an oral tablet indicated to treat active psoriatic arthritis in adults. Otezla has a single contraindication: known hypersensitivity to the active ingredient or any excipients in Otezla tablets.
Although several medications and dietary factors have been implicated, as causes of gout, much of the risk of developing the condition is controlled through genetics, and the pathophysiology of the disease is incompletely understood.
The choice of an appropriate disease-modifying antirheumatic drug (DMARD) is complicated by the availability of several agents and the lack of comparative effectiveness studies. Until recently, the scientific consensus did not favor any agent over another as the most appropriate initial biologic DMARD for patients with rheumatoid arthritis (RA).
Although not completely understood, the pathogenesis of rheumatoid arthritis is thought to involve an external trigger (eg, trauma, cigarette smoke, infection) that induces an autoimmune reaction, resulting in synovial hypertrophy and chronic joint inflammation in persons who are genetically susceptible.
The AJMCtv Peer Exchange video editorial series provides a multi-stakeholder perspective on important issues facing medical professionals in the evolving healthcare landscape. The recent multi-part "Rare Diseases" panel discussion featured several segments that focused on the treatment of hemophilia.
With the emergence of new therapies targeted to specific drivers of melanoma and the approval of two new agents that demonstrate improvements in overall survival there appears to be fresh hope for improving outcomes in a cancer that, after metastasis, formerly left patients with very little hope.
The medical community welcomed two new direct-acting antiviral (DAA) agents for HCV-telaprevir (Incivek, Vertex Pharmaceuticals Incorporated) and boceprevir (Victrelis, Merck & Co., Inc.)-with an excitement that hadn't been seen since 1990.
It's always hard to know how many new therapies will make it all the way through a drug development pipeline.There are 12 combination therapies in phase II trials, 19 individual agents in phase II, and five more in phase III.